多西紫杉醇周方案对老年晚期非小细胞肺癌生活质量的影响

Quality of life and curative effect of terminal non- small cell lung cancer treated with Docetaxel

目的探讨多西紫杉醇（docetaxel）每周用药时辰化疗对老年晚期非小细胞肺癌（NSCLC）患者疗效和生活质量的影响，寻求对NSCLC有效的干预方法。方法72例老年晚期NSCLC患者按性别、年龄、UICC-TNM分期和细胞病理1：1配对，分成两组，所有患者均为初次化疗。治疗组采用多西紫杉醇每周用药时辰化疗，对照组应用足叶乙甙联合卡铂（CE）方案，治疗前和治疗后1个月、2个月分别用肺癌患者生活质量量表（QOL）测评。结果共配成36对，治疗组有效率和临床控制率（58．33％，94．44％）均明显高于对照组（30．56％，72．22％）；治疗组治疗后1个月、2个月QOL评分均明显高于对照组（P〈0．05）。结论多西紫杉醇每周用药时辰化疗对NSCLC患者QOL的影响优于CE方案，说明多西紫杉醇是一种适合于老年晚期NSCLC患者的化疗药物。

Objective Used Docetaxel weekly to treat the old patients with advanced non-small cell lung cancer（NSCLC） ,observed and studied the curative effect and life quality. And to search the effective method for NSCLC. Methods 72 cases of NSCLC patients were paired into two groups,according to gender,age, UICC-TNM and cellular pathology. All the patients were the first time to accept the chemotherapy. Used Docetaxel weekly to treat the first group,and CE（ Etoposide and Carboplatin） for the second one. Before the treatment and in the first month,second month after the treatment,judged both groups by QOL. Results The percentage of efficiency and CBR of the first group （58. 33% and 94. 44% ） was higher significantly the second group（30. 56% and 72. 22% ） ;in the first month and the second month after treatment,the QOL score than that of the first group was higher than that of the second group （ P 〈 0. 05 ）. Conclusion In contrast of curative effect and quality of life, Docetaxel weekly is better than CE for the patients of advanced NSCLC, so Docetaxel is one of the best chemotherapy agents for the eldely patients with NSCLC.